Development of Resistance towards Artesunate in MDA-MB-231 Human Breast Cancer Cells
2011

Artesunate Resistance in Breast Cancer Cells

publication Evidence: moderate

Author Information

Author(s): Bachmeier Beatrice, Fichtner Iduna, Killian Peter H., Kronski Emanuel, Pfeffer Ulrich, Efferth Thomas

Primary Institution: Ludwig-Maximilians-University, Munich, Germany

Hypothesis

Can artesunate induce resistance in breast cancer cells?

Conclusion

Artesunate induces resistance in highly metastatic breast cancer cells, leading to reduced apoptosis and increased expression of anti-apoptotic factors.

Supporting Evidence

  • Artesunate treatment led to increased expression of anti-apoptotic bcl-2 and decreased expression of pro-apoptotic bax.
  • Highly metastatic MDA-MB-231 cells showed resistance to artesunate, while less tumorigenic MDA-MB-468 cells did not.
  • Activation of NFκB and AP-1 transcription factors was associated with the development of resistance.

Takeaway

This study found that a drug called artesunate, which is used to treat malaria, can make breast cancer cells stronger and less likely to die, which is not what we want.

Methodology

The study used in vitro and in vivo experiments to analyze the effects of artesunate on breast cancer cell lines and tumor growth in mice.

Limitations

The study primarily focused on two breast cancer cell lines and may not represent all breast cancer types.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0020550

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication